Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas

Acta Neuropathol Commun. 2019 Jul 26;7(1):121. doi: 10.1186/s40478-019-0778-3.

Authors

Kanish Mirchia¹, Matija Snuderl², Kristyn Galbraith¹, Kimmo J Hatanpaa³, Jamie M Walker^{4

5}, Timothy E Richardson⁶

Affiliations

¹ Department of Pathology, State University of New York, Upstate Medical University, Syracuse, NY, 13210, USA.
² Department of Pathology, New York University Langone Health, New York City, NY, 10016, USA.
³ Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
⁴ Department of Pathology, University of Texas Health Science Center, San Antonio, TX, 78229, USA.
⁵ Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, TX, 78229, USA.
⁶ Department of Pathology, State University of New York, Upstate Medical University, Syracuse, NY, 13210, USA. [email protected].

No abstract available

Keywords: Astrocytoma; CNA; CNV; Copy number alterations; Copy number variation; GBM; Glioblastoma; Glioma; IDH mutation; TCGA.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Astrocytoma / diagnosis
Astrocytoma / genetics*
Astrocytoma / mortality
Brain Neoplasms / diagnosis
Brain Neoplasms / genetics*
Brain Neoplasms / mortality
DNA Copy Number Variations / genetics*
Female
Humans
Isocitrate Dehydrogenase / genetics*
Male
Mutation / genetics*
Neoplasm Grading / methods
Prognosis
Survival Rate / trends

Substances

IDH2 protein, human
Isocitrate Dehydrogenase
IDH1 protein, human